Results 11 to 20 of about 19,377 (264)
Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease [PDF]
Frontiers in Medicine, 2020 The complex nature of inflammatory bowel disease (IBD) often results in treatment failure for many patients. With some patients cycling through multiple therapies before achieving a sustained period of remission, the ability to predict a patient's ...
Jack S. Cornish +3 more
doaj +2 more sources
Thiopurine S -methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs [PDF]
European Journal of Clinical Pharmacology, 2018 Objective: More than 11% of the Caucasian population are heterozygous or homozygous carriers of thiopurine S-methyltransferase (TPMT) mutants and are at risk for toxic side effects when treated with thiopurine drugs.
Fried, M. +5 more
core +4 more sources
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update. [PDF]
Clin Pharmacol TherThiopurine methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) are key enzymes that catabolize thiopurines. Decreased or no‐function alleles in TPMT and NUDT15 are associated with reduced or no enzyme activity and predictive of pronounced adverse effects, including severe myelosuppression, that may occur among individuals treated with standard ...
Maillard M +18 more
europepmc +2 more sources
Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis [PDF]
Intestinal Research, 2015 Background/AimsThe long-term clinical outcomes of patients with bio-naive ulcerative colitis (UC) who maintain remission with thiopurine are unclear.
Satoshi Yamada +8 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Backgound: The high incidence of thiopurine-induced myelosuppression in Asians is known to be attributable to genetic variation in thiopurine metabolism.
Kanyarat Khaeso +13 more
doaj +1 more source
Pharmacogenetics and Genomics, 2010 The thiopurine drugs are purine antimetabolites widely used in the treatment of acute lymphoblastic leukemia, autoimmune disorders (e.g. Crohn’s disease and rheumatoid arthritis) and of organ transplant recipients. As inactive prodrugs, 6-mercaptopurine (6-MP), 6-thioguanine (6-TG) and azathioprine require intracellular activation, catalyzed by ...
Gianluigi Zaza +11 more
openaire +7 more sources
Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. [PDF]
PLoS ONE, 2015 Thiopurine drugs are well established treatments in the management of inflammatory bowel disease (IBD), but their use is limited by significant adverse drug reactions (ADRs).
Yue-Ping Liu +8 more
doaj +1 more source
Scientific Reports, 2022 The thiopurine derivatives azathioprine (AZA), mercaptopurine (MP) and tioguanine (TG) remain standard treatment of inflammatory bowel disease (IBD). The immune suppressive effect of thiopurines is primarily based on blocking the Ras-related C3 botulinum
Debbie S. Deben +7 more
doaj +1 more source
Frontiers in Oncology, 2021 Overexpression of the deubiquitinase USP2a leads to stabilization of fatty acid synthase (FAS), the levels of which are often elevated in aggressive human cancers.
Chiao-Pei Cheng +4 more
doaj +1 more source
Future Science OA, 2023 Primary hepatic lymphoma is a rare variant of non-Hodgkin's lymphoma with an incidence of 0.016% of all non-Hodgkin lymphomas. The most common histologic subtype is large diffuse B-cell lymphoma.
Salma Merhaben +6 more
doaj +1 more source